结直肠癌患者血清miR-92a水平测定的临床意义

Clinical significance of serum miR-92a in colorectal cancer patients

目的探讨血清miR-92a在结直肠癌(CRC)诊断和预后判断中的价值。方法 78例结直肠癌患者,分别为无转移组40例和肝转移组38例,同时募集40例健康志愿者为健康对照组。应用实时荧光定量PCR法检测miR-92a水平。结果结直肠癌患者血清miR-92a水平显著高于健康对照组(P<0.01),用于结直肠癌诊断时的灵敏度为75.3%,特异度为88.3%;结直肠癌肝转移组血清miR-92a水平显著高于无转移组(P<0.05),鉴别转移性与无转移性CRC患者的敏感性为78.6%,特异性为86.6%。结论血清miR-92a可能是一种新的生物学标记物用于结直肠癌患者的早期诊断,其水平上调与结直肠癌患者预后有关。

Objective To investigate the value of serum miR-92a in the diagnosis and prognosis prediction of colorectal cancer （CRC）. Methods A total of 78 cases of CRC were divided into non-metastasis group （n=40） and liver metastasis group （n=38）, and 40 healthy volunteers were put into health control group. The level of miR-92a was detected by real-time RT-PCR. Results The level of serum miR-92a was significantly higher in CRC patients than in the control group （P〈0.01）. The sensitivity was 75.3%and the specificity was 88.3% in discriminating CRC. The liver metastasis group had higher level of serum miR-92a than the non-metastasis group, （P〈0.05）. The sensitivity was 78.6%and the specificity was 86.6%in discriminating metastatic or non-metastatic CRC. Conclusion Serum miR-92a can become a new biomarker for early diagnosis of CRC patients, and its level is associated with prognosis of CRC patients.